MedDataX Logo

Study Evaluating Etanercept in Patients With Rheumatoid Arthritis(RA), Juvenile Idiopathic Arthritis (JIA), or Psoriatic Arthritis (PsA) in Spain

NCT ID: NCT00195377

Last Updated: 2009-06-18

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

1000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2003-04-30

Study Completion Date

2006-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to assess the safety of etanercept in patients with rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA) or psoriatic arthritis (PsA) in Spain

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study Evaluating Etanercept in Patients With Rheumatoid Arthritis Who Completed Trial 0881A1-301-EU in Spain

NCT00195364

Rheumatoid Arthritis Inflammation
COMPLETED

Study Evaluating Etanercept in 3 Subtypes of Childhood Arthritis

NCT00962741

Arthritis, Juvenile Idiopathic
COMPLETED PHASE3

Study Evaluating the Safety and Efficacy of Etanercept in Patients With Psoriatic Arthritis Treated by Rheumatologists

NCT00293722

Arthritis, Psoriatic Psoriasis Skin Diseases, Papulosquamous
COMPLETED

Study Evaluating Etanercept Plus Methotrexate in Early Rheumatoid Arthritis

NCT00913458

Active Rheumatoid Arthritis Arthritis, Rheumatoid Rheumatoid Arthritis
COMPLETED PHASE4

Study Evaluating the Safety and Efficacy of Etanercept in Patients With Psoriatic Arthritis Treated by Dermatologists

NCT00293709

Arthritis, Psoriatic Psoriasis Skin Diseases, Papulosquamous
COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Arthritis, Psoriatic Arthritis, Rheumatoid

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Etanercept

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* RA or PsA in whom DMARDs/antiTNF antibodies/anti IL1 has been insufficient or inappropriate
* Children from 4 to 17 years old with JIA polyarticular

Exclusion Criteria

* Clinically significant abnormal screening lab values
* Patients who are planning to undergo elective surgery during the study period.
* Other current autoimmune connective tissue diseases
Minimum Eligible Age

4 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

Sponsor Role lead

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Medical Monitor

Role: STUDY_DIRECTOR

Wyeth is now a wholly owned subsidiary of Pfizer

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Madrid, Madrid, Spain

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Spain

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

101393

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Extension Study Evaluating Etanercept in 3 Subtypes of Childhood Arthritis
NCT01421069 COMPLETED PHASE3
Study Evaluating Etanercept in Subjects With Ankylosing Spondylitis in Spain
NCT00873730 COMPLETED PHASE4
Study Comparing Etanercept in Combination With Methotrexate in Subjects With Rheumatoid Arthritis
NCT00565409 COMPLETED PHASE4
Study Evaluating the Efficacy and Safety of Etanercept
NCT00546533 COMPLETED PHASE4
Study Evaluating Etanercept on Skin and Joint Disease in Psoriatic Arthritis
NCT00245960 COMPLETED PHASE4
Study to Evaluate the Ability of Subjects With Rheumatoid Arthritis or Psoriatic Arthritis to Effectively Use a Reusable Autoinjector to Self-inject Etanercept
NCT01901185 COMPLETED PHASE3
Study Evaluating the Safety of Etanercept in Rheumatoid Arthritis, Ankylosing Spondylitis and Psoriatic Arthritis
NCT00273858 TERMINATED
Intra-Articular Injection of Etanercept in Patient Suffering From Rheumatoid Arthritis : a Double-Blind Randomized Study
NCT00522184 COMPLETED PHASE3
Open-Label Study Comparing Etanercept to Conventional Disease Modifying Antirheumatic Drug (DMARD) Therapy
NCT00848354 COMPLETED PHASE4
Study Evaluating Workload, Clinical and Therapeutic Management of Psoriatic Arthritis
NCT00580632 COMPLETED
Study of Etanercept Monotherapy vs Methotrexate Monotherapy for Maintenance of Rheumatoid Arthritis Remission
NCT02373813 COMPLETED PHASE3
Study Evaluating the Safety of Enbrel (Etanercept)
NCT00683384 COMPLETED
Study Comparing Perceptions and Satisfaction for Two Different Delivery Mechanisms for Etanercept
NCT00459706 COMPLETED PHASE3
Study Evaluating the Efficacy of Enbrel (Etanercept) in Subjects in Japan
NCT00503503 COMPLETED
A Study To Evaluate The Efficacy Of Enbrel (REGISTERED) Etanercept Over A Period Of 12 Months In The Routine Treatment Of Patients With Rheumatoid Arthritis, Axial Spondyloarthritis, Psoriatic Arthritis, Or Plaque Psoriasis.
NCT02486302 COMPLETED
Study to Assess the Immunogenicity, Safety, and Efficacy of High Capacity Process Etanercept in Rheumatoid Arthritis Subjects
NCT02378506 COMPLETED PHASE3
An Open-Label, Multicentre, Long-Term Extension Study of Etanercept in Ankylosing Spondylitis
NCT00421980 COMPLETED PHASE3
Study to Assess the Safety and Efficacy of Etanercept in Patients Treated Over the Long-term in Real-world Clinical Practice, Using Data Collected by the British Society of Rheumatology Biologics Registry
NCT01646385 COMPLETED
Study Evaluating the Clinical and Therapeutic Management of Rheumatoid Arthritis in Spain
NCT00881881 COMPLETED
Etanercept and Methotrexate in Combination or as Monotherapy in Psoriatic Arthritis
NCT02376790 COMPLETED PHASE3
Open Label, Dose-Regimen Study Evaluating Etanercept 50 mg Once-Weekly In Japanese Subjects With RA
NCT00418717 COMPLETED PHASE3
Study Evaluating The Use Of Etanercept In Patients With Ankylosing Spondylitis
NCT00544557 COMPLETED
Evaluating Efficacy and Safety of Etanercept 50 mg Twice Weekly (BIW) in Rheumatoid Arthritis (RA) Subjects Who Are Sub-Optimal Responders to Etanercept 50 mg Once Weekly (QW)
NCT00115219 COMPLETED PHASE4
Study Comparing Etanercept (ETN) Against a Placebo for Etanercept on a Background Nonsteroidal Anti Inflammatory Drug (NSAIDs) in the Treatment of Early Spondyloarthritis (SpA) Patients Who do Not Have X-ray Structural Changes
NCT01258738 COMPLETED PHASE3
Safety and Efficacy of Etanercept (Recombinant Human Tumor Necrosis Factor Receptor Fusion Protein [TNFR:Fc]) in Children With Juvenile Rheumatoid Arthritis (JRA)
NCT03780959 COMPLETED PHASE2/PHASE3